CoChat

Reversal of Autoimmune Toxicity and Loss of Tumor Response by Interleukin-17 Blockade

Esfahani, Khashayar, Miller, Wilson H. · 2017 · New England Journal of Medicine

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

In a patient with colon cancer and a history of autoimmunity, skin and gastrointestinal toxicity developed after the receipt of pembrolizumab. Interleukin-17 blockade reversed the autoimmunity but led to tumor progression.

Overview

Integrity signals

Registry

Crossref · 10.1056/nejmc1703047

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 5 references

Cited by

See all 200

Metadata

Authors
Esfahani, K., & Miller, W. H.
Affiliations
McGill University (CA)
Venue
New England Journal of Medicine
Published
2017-05-18
Volume
376
Issue
20
Pages
1989-1991
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2615312978
Cited by
200
References
5
Citations by year
2026: 10 · 2025: 18 · 2024: 27 · 2023: 22 · 2022: 14 · 2021: 30 · 2020: 33 · 2019: 28 · 2018: 15 · 2017: 3
FWCI
9.53
Type
journal article
Language
en
Open access
closed
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
pembrolizumab, immune checkpoint inhibitor toxicity, autoimmune toxicity, colon cancer, tumor progression, immune-related adverse events
MeSH terms
Antibodies, Monoclonal, Autoimmune Diseases, Colonic Neoplasms, Crohn Disease, Exanthema, Humans, Male, Middle Aged, Interleukin-17, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Reversal of Autoimmune Toxicity and Loss of Tumor Response by Interleukin-17 Blockade. https://app.cochat.ai/papers/10.1056/nejmc1703047
The paper
Esfahani, K., & Miller, W. H. (2017). Reversal of Autoimmune Toxicity and Loss of Tumor Response by Interleukin-17 Blockade. New England Journal of Medicine. https://doi.org/10.1056/nejmc1703047

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.